Weiqi Nian

Dr. Weiqi Nian


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LLLixian Li
Lixian Li
XZXiaodong Zheng
Xiaodong Zheng
QZQi Zhou
Qi Zhou
NVNathaniel Villanueva
Nathaniel Villanueva
WNWeiqi Nian
Weiqi Nian
Tao HuanTao Huan
Tao Huan
Triple negative breast cancer (TNBC) is a devastating cancer disease characterized by its poor prognosis, distinct metastatic patterns, and aggressive biological behavior. Research indicates that the prevalence and presentation of TNBC varies among races, with Asian TNBC patients more commonly presenting with large invasive tumors, high node positivity, and high histologic grade. In this work, we applied ultra-high performance liquid chromatography-high resolution mass spectrometry (UHPLC-HRMS)-based metabolomics to discover metabolic signatures in Asian female TNBC patients. Serum samples from 31 TNBC patients and 31 healthy controls (CN) were involved in this study. A total of 2860 metabolic features were detected in the serum samples. Among them, 77 metabolites, whose levels were significantly different between TNBC with CN, were confirmed. Using multivariate statistical analysis, literature mining, metabolic network and pathway analysis, we performed an in-depth study of the metabolic alterations in the Asian TNBC population. In addition, we discovered a panel of metabolic signatures that are highly correlated with the 5-year survival rate of the TNBC patients. This metabolomic study provides a better understanding of the metabolic details of TNBC in the Asian population.

17 August 2022 in Biosensors
Verified
Journal Article
Open access
PDF file
KWKe Wang
Ke Wang
ZPZhijia Peng
Zhijia Peng
Xiaogang LinXiaogang Lin
Xiaogang Lin
WNWeiqi Nian
Weiqi Nian
XZXiaodong Zheng
Xiaodong Zheng
Jie Jayne WuJie Jayne Wu
Jie Jayne Wu
Early diagnosis and treatment have always been highly desired in the fight against cancer, and detection of circulating tumor DNA (ctDNA) has recently been touted as highly promising for early cancer-screening. Consequently, the detection of ctDNA in liquid biopsy is gaining much attention in the field of tumor diagnosis and treatment, which has also attracted research interest from industry. However, it is difficult to achieve low-cost, real-time, and portable measurement of ctDNA in traditional gene-detection technology. Electrochemical biosensors have become a highly promising solution to ctDNA detection due to their unique advantages such as high sensitivity, high specificity, low cost, and good portability. Therefore, this review aims to discuss the latest developments in biosensors for minimally invasive, rapid, and real-time ctDNA detection. Various ctDNA sensors are reviewed with respect to their choices of receptor probes, designs of electrodes, detection strategies, preparation of samples, and figures of merit, sorted by type of electrode surface recognition elements. The development of biosensors for the Internet of Things, point-of-care testing, big data, and big health is analyzed, with a focus on their portable, real-time, and non-destructive characteristics.

5 November 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
HZHai-Wei Zhang
Hai-Wei Zhang
EWEn-Wen Wang
En-Wen Wang
LLLi-Xian Li
Li-Xian Li
SYShou-Hui Yi
Shou-Hui Yi
LLLu-Chun Li
Lu-Chun Li
WNWeiqi Nian
Weiqi Nian
A regulatory loop involving miR-29c and Sp1 elevates the TGF-β1 mediated epithelial-to-mesenchymal transition in lung cancer

5 January 2021 in International Journal of Polymer Science
Verified
Journal Article
Open access
PDF file
LLLixian Li
Lixian Li
YHYongpeng He
Yongpeng He
XZXiaodong Zheng
Xiaodong Zheng
LYLin Yi
Lin Yi
WNWeiqi Nian
Weiqi Nian
Hydrogels with three-dimensional network structure, hydrophilic, and insoluble in water which are ideal carrier materials for intelligent drug delivery systems. Intelligent hydrogel has become a research frontier and hotspot because of its intelligence, high efficiency, safety, and convenience in drug controlled and prolonged release. It has a broad application prospect in the medicine and biomedicine fields and can lead the medicine fields into a new era of “precise treatment.” Based on the latest research progress, the main preparation methods of hydrogel and the development of the drug delivery system are briefly introduced. The most promising three intelligent hydrogels in the human physiological environment, namely, pH responsiveness, temperature responsiveness, and pH/temperature dual responsiveness, are emphatically reviewed. Their release mechanisms, targeting transport, and controlled-prolonged release of drug are also discussed. In addition, some suggestions for the main problems and future development were given.

1 September 2019 in Medicine
Verified
Journal Article
Open access
YHYong-Peng He
Yong-Peng He
LLLi-Xian Li
Li-Xian Li
JTJia-Xi Tang
Jia-Xi Tang
LYLin Yi
Lin Yi
YZYi Zhao
Yi Zhao
LGLin Gan
Lin Gan
Background: The aim of our study was to assess the value of serum human epididymis protein 4 (HE4) to diagnose lung cancer and provide reliable scientific conclusions to guide clinical practice. Methods: A systematic search of the PubMed, EMBASE, Cochrane Library, Chinese National Knowledge Infrastructure, Chinese Biomedical Literature, and WANFANG databases was conducted to identify all studies examining serum HE4 in the diagnosis of lung cancer published up to June, 2017. The Quality Assessment of Diagnostic Accuracy Studies tool was used to evaluate the methodological quality of each trial. The meta-analysis was performed using STATA software and Review Manager 5.3. Results: There were 21 studies involving 1883 cases and 1696 controls included in our meta-analysis. The pooled sensitivity and specificity of HE4 for diagnosing lung cancer were 0.73 (95% confidence interval [CI] 0.68–0.78) and 0.86 (95% CI 0.81–0.91), respectively. The positive likelihood ratio and negative likelihood ratio were 5.4 (95% CI 3.8–7.5) and 0.31 (95% CI 0.26–0.37), respectively. The diagnostic odds ratio was 17 (95% CI 12–26). The area under the curve of the summary receiver-operating characteristic curve was 0.86 (95% CI 0.83–0.89). Race, assay method, type of cancer, sample size, and publication date might be sources of heterogeneity in our meta-analysis. Subgroup analyses showed that the sensitivity in Caucasians was higher than that in Asians (0.81, 95% CI 0.71–0.91; and 0.71, 95% CI 0.66–0.77, respectively), but the specificity in Asians was better than that in Caucasians (0.87, 95% CI 0.81–0.92; and 0.85, 95% CI 0.73–0.97, respectively). The chemiluminescent microparticle immunoassay had the highest sensitivity, with 0.79 (95% CI 0.73–0.97), and the enzyme-linked immunosorbent assay had the highest specificity, with 0.87 (95% CI 0.79–0.94). HE4 had high diagnostic efficacy when screening for small cell lung cancer with the highest specificity (0.90, 95% CI 0.77–1.00). Conclusions: HE4 is a relatively promising and effective biomarker for the diagnosis of lung cancer. Furthermore, given the limitations of our study, additional large-scale and well-designed studies are needed in the future.

11 January 2019 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
LLLiu Liu
Liu Liu
YWYan Wu
Yan Wu
CBChunxiang Bian
Chunxiang Bian
MNMuhammad Farrukh Nisar
Muhammad Farrukh Nisar
MWMei Wang
Mei Wang
JZJulia Li Zhong
Julia Li Zhong
Despite therapeutic advancements (e.g. B-RAF inhibitors) targeting cutaneous melanoma, many cellular processes, including inducible heme oxygenase 1 (HO-1), counteract treatments for malignancies. So there is an urgent need to find biological treatment targets, develop new therapeutic approaches and achieve longer responses. This study aimed to explore the relationship of HO-1 and B-Raf via mediating ERK1/2 signaling on cell cycle in melanoma. Immunohistochemistry was applied to evaluate the levels of HO-1 and B-Raf expression in melanoma tissues and adjacent healthy tissues. Co-immunoprecipitation (Co-IP) assessed the interaction of HO-1 with B-Raf. Further study overexpression and knock-down of HO-1 in A375 cell lines, especially knockout HO-1 using CRISPR-Cas9, verified HO-1 regulate cell proliferation in vivo and in vitro. Finally, Western blot analysis and qRT-PCR were performed to investigate the mechanisms by which HO-1 mediates cell cycle by B-RAF-ERK1/2 signaling. First, histology and Co-IP show that HO-1 interacts with B-Raf directly in melanoma tissue. Further study illustrated that HO-1 overexpression promotes melanoma cell proliferation while HO-1 reduction represses melanoma cell proliferation because of HO-1 affects cell cycle. Mechanistic studies revealed that HO-1 was associated with a marked activation of B-RAF-ERK1/2 signaling and led to CDK2/cyclin E activation, thereby promoting melanoma proliferation. Our result reveals a previously unknown mechanism that the HO-1-B-RAF-ERK axis plays an important role in melanoma cell proliferation. Therapeutic target on HO-1 could be a novel method for treating melanoma.